Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Mastocytosis

6

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

4

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Chloride channels

4

G-protein coupled receptor 35

4

calcium ion import

4

mast cell activation

4

Platelet-derived growth factor receptor alpha

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1973

4

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

6

Palliative

4

Preventing

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

4

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Fisons

4

AB Science

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

EPA CompTox

6

FDA UNII

6

PUBCHEM

6

EVMPD

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

2

ALIMENTARY TRACT AND METABOLISM

1

DERMATOLOGICALS

1

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

2

ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS

1

NASAL PREPARATIONS

1

OPHTHALMOLOGICALS

1

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ADRENERGICS, INHALANTS

1

DECONGESTANTS AND ANTIALLERGICS

1

DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE

1

INTESTINAL ANTIINFLAMMATORY AGENTS

1

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics

1

Agents for atopic dermatitis, excluding corticosteroids

1

Antiallergic agents, excl. corticosteroids

1

Other antiallergics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CROMOLYN

Y0TK0FS77W

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1973

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

mast cell activation

calcium ion import

G-protein coupled receptor 35

Chloride channels

Conditions:

Allergic rhinitis

Allergic conjunctivitis

Allergic rhinitis

Vernal keratoconjunctivitis

Bronchial asthma

Cromolyn is a mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells, which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the rele...

ase of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Cromolyn is indicated in the management of patients with mastocytosis, prophylaxis (long-term control) of bronchial asthma, prevention of exercise-induced bronchospasm, prevention and treatment of seasonal and perennial allergic rhinitis The most frequently reported adverse reactions attributed to cromolyn sodium treatment were: throat irritation or dryness, bad taste, cough, wheeze, nausea.

MASITINIB

M59NC4E26P

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Platelet-derived growth factor receptor alpha

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Tyrosine-protein kinase Lyn

Conditions:

Dog mast cell tumours

Alzheimer’s disease

Amyotrophic lateral sclerosis

Multiple sclerosis

Gastrointestinal stromal tumor

Colorectal cancer

Rheumatoid arthritis

Multiple myeloma

Malignant melanoma

Pancreatic cancer

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be develope...

d in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases. AB Science is developing masitinib in multiple sclerosis and alzheimer's disease. Masitinib targets kinases, including c-Kit, PDGFR, and Lyn. It is used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet.

CROMOGLICATE LISETIL

VOZ07VZP8G

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1973

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

mast cell activation

calcium ion import

G-protein coupled receptor 35

Chloride channels

Conditions:

Allergic rhinitis

Allergic conjunctivitis

Allergic rhinitis

Vernal keratoconjunctivitis

Bronchial asthma

Cromolyn is a mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells, which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the rele...

ase of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Cromolyn is indicated in the management of patients with mastocytosis, prophylaxis (long-term control) of bronchial asthma, prevention of exercise-induced bronchospasm, prevention and treatment of seasonal and perennial allergic rhinitis The most frequently reported adverse reactions attributed to cromolyn sodium treatment were: throat irritation or dryness, bad taste, cough, wheeze, nausea.

CROMOGLICATE LISETIL HYDROCHLORIDE

W7074H45IM

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1973

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

mast cell activation

calcium ion import

G-protein coupled receptor 35

Chloride channels

Conditions:

Allergic rhinitis

Allergic conjunctivitis

Allergic rhinitis

Vernal keratoconjunctivitis

Bronchial asthma

Cromolyn is a mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells, which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the rele...

ase of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Cromolyn is indicated in the management of patients with mastocytosis, prophylaxis (long-term control) of bronchial asthma, prevention of exercise-induced bronchospasm, prevention and treatment of seasonal and perennial allergic rhinitis The most frequently reported adverse reactions attributed to cromolyn sodium treatment were: throat irritation or dryness, bad taste, cough, wheeze, nausea.

CROMOLYN SODIUM

Q2WXR1I0PK

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1973

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

mast cell activation

calcium ion import

G-protein coupled receptor 35

Chloride channels

Conditions:

Allergic rhinitis

Allergic conjunctivitis

Allergic rhinitis

Vernal keratoconjunctivitis

Bronchial asthma

Cromolyn is a mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells, which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the rele...

ase of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Cromolyn is indicated in the management of patients with mastocytosis, prophylaxis (long-term control) of bronchial asthma, prevention of exercise-induced bronchospasm, prevention and treatment of seasonal and perennial allergic rhinitis The most frequently reported adverse reactions attributed to cromolyn sodium treatment were: throat irritation or dryness, bad taste, cough, wheeze, nausea.

MASITINIB MESYLATE

ZK89EG3A18

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Platelet-derived growth factor receptor alpha

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Tyrosine-protein kinase Lyn

Conditions:

Dog mast cell tumours

Alzheimer’s disease

Amyotrophic lateral sclerosis

Multiple sclerosis

Gastrointestinal stromal tumor

Colorectal cancer

Rheumatoid arthritis

Multiple myeloma

Malignant melanoma

Pancreatic cancer

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be develope...

d in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases. AB Science is developing masitinib in multiple sclerosis and alzheimer's disease. Masitinib targets kinases, including c-Kit, PDGFR, and Lyn. It is used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1